N
NKTR icon

Natixis’s Nektar Therapeutics NKTR Stock Holding History

Natixis’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.3K Hold
685
– – ﹤0.01% 983
2025
Q4 		$29K Buy
+685
New +$38.3K ﹤0.01% 1024
2022
Q2 		– Sell
-3,146
Closed -$254K – 1286
2022
Q1 		$254K Buy
+3,146
New +$466K ﹤0.01% 1082
2019
Q3 		– Sell
-2,792
Closed -$1.49M – 887
2019
Q2 		$1.49M Buy
2,792
+145
+5% +$72.7K 0.01% 484
2019
Q1 		$1.3M Sell
2,647
-749
-22% -$444K 0.01% 547
2018
Q4 		$1.67M Buy
3,396
+1,514
+80% +$914K 0.01% 446
2018
Q3 		$1.72M Buy
+1,882
New +$1.61M 0.01% 504
2018
Q1 		– Sell
-1,072
Closed -$960K – 946
2017
Q4 		$960K Buy
1,072
+287
+37% +$170K 0.01% 505
2017
Q3 		$283K Buy
+785
New +$246K ﹤0.01% 935
2017
Q2 		– Sell
-1,102
Closed -$388K – 940
2017
Q1 		$388K Buy
+1,102
New +$248K ﹤0.01% 590

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Natixis's NKTR Position: Q1 2026 in Review

Natixis held its Nektar Therapeutics (NKTR) position steady in Q1 2026 at 685 shares worth $49.3K. The position accounts for ﹤0.01% of the portfolio, ranked #983.

Natixis first reported a position in NKTR in Q1 2017 and has held it in 10 quarters since. The position peaked at $1.72M in Q3 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Natixis held 685 shares of Nektar Therapeutics worth $49.3K as of Q1 2026.
  • Natixis left its Nektar Therapeutics share count unchanged in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of Natixis's portfolio in Q1 2026, its #983 holding.
  • Natixis first reported a position in Nektar Therapeutics in Q1 2017 and has held it in 10 quarters since.
  • Natixis's Nektar Therapeutics position peaked at $1.72M in Q3 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.